Psychedelic Therapy Is Expanding—But Something Deeper Is Happening
In April 2026, Donald Trump signed an executive order directing federal agencies to accelerate research into psychedelic-assisted therapy.
On the surface, this looks like a meaningful shift—an attempt to expand treatment options for depression, PTSD, addiction, and other forms of suffering that don’t always respond to conventional care. Agencies like the Food and Drug Administration are being encouraged to move more quickly, to create pathways that allow substances like psilocybin, MDMA, and ibogaine to be studied, approved, and eventually used in clinical settings.
It’s easy to read this as progress. In many ways, it is.
And yet, sitting with this as someone who was once involved in psychedelic research, I find myself tracking something else alongside the momentum. Not a clear opposition—more like a quiet unease that lives next to the hope.
Because what’s happening right now isn’t just about access.
It’s about speed.
When the Pace Picks Up, Other Things Change Too
There’s a certain kind of energy that comes with something being “fast-tracked.” It carries urgency, promise, and often a sense that we’re finally catching up to something important.
But in clinical work, I’ve learned that not everything benefits from acceleration.
Psychedelic experiences can open very tender, disorganized, or deeply buried material. They can soften defenses that have been in place for good reason. They can create states of vulnerability that are profound—and not always easy to navigate afterward.
When the field moves quickly, the question becomes:
Are we building enough structure around the experience to hold what it opens?
Or are we focusing more on getting people to the experience itself?
That distinction matters more than it might seem.
What I Saw From the Inside
There was a time when I felt aligned with this work. Psychedelics seemed to offer something that traditional approaches often couldn’t—a way into grief, trauma, and disconnection that didn’t rely on talking around the edges.
And that part is real.
But being inside the research world, I also began to notice a different layer.
There was pressure—sometimes subtle, sometimes not—to move things forward. To demonstrate efficacy. To show results. To make the case that these treatments should be approved and scaled.
Again, none of that is inherently wrong. It’s how medical systems operate.
But when that pressure increases, other things can get less attention than they need.
Things like:
how carefully facilitators are trained
how power is held in altered states
how vulnerable participants can become
what happens when something goes wrong
These are not abstract concerns. They are clinical realities.
The Part That Doesn’t Get Talked About Enough
One of the more difficult aspects of this field—and one that is often minimized in public conversations—is the issue of boundary violations and sexual misconduct in psychedelic therapy spaces.
These are not just isolated incidents.
They are connected to the nature of the work itself.
Psychedelic states can increase suggestibility. They can create deep emotional openness, dependency, even a kind of trust that bypasses usual protective instincts. In those states, the role of the therapist or guide carries enormous power.
When that power is not held with care—or when systems move faster than their ethical frameworks—harm can happen.
And it has.
This isn’t comfortable to talk about. It complicates the narrative.
But it’s part of the reality that needs to be held alongside the promise.
The Role of Money—And Why It Matters
There is also a financial layer to all of this that is hard to ignore.
As psychedelic therapy moves closer to mainstream approval, there is increasing investment—from pharmaceutical companies, startups, and private equity. There is a sense that this is the “next frontier” in mental health treatment.
Which means there is a lot of money at stake.
And when money enters the picture at that scale, it inevitably shapes the direction of the field.
Questions begin to shift, even subtly:
What can be patented?
What can be scaled?
What can be delivered efficiently?
Not:
What requires time?
What resists standardization?
What needs to remain relational rather than transactional?
Again, this isn’t about bad actors. It’s about systems doing what systems do.
But it does create tension—especially when the work itself asks for something slower, more attuned, more human.
The Indigenous Layer Still Matters
At the same time, these medicines don’t originate in the systems now developing them.
They come from indigenous traditions where they are embedded in relationships—ritual, community, lineage, responsibility.
That context isn’t just cultural. It’s part of what makes the work safe and meaningful.
As psychedelics move into Western clinical frameworks, that layer often becomes background rather than foundation.
And for many, that raises an important question:
Can something rooted in relationship be fully translated into a system built around treatment and delivery?
There’s no simple answer. But it’s a question worth staying close to.
Why Integration Is Where I Landed
All of this is part of what led me to step away from psychedelic research.
Not because I stopped believing in the potential of these experiences.
But because I became more interested in what happens after.
Psychedelic experiences can open something.
Integration is what helps that opening become meaningful.
It’s where the material that surfaces gets metabolized. Where insight becomes lived change. Where the nervous system has time to reorganize, rather than being pushed into the next experience or outcome.
Without that, even powerful experiences can become disorienting, or fade without lasting impact.
With it, something deeper can take root.
Holding Both Sides
There is a way to talk about psychedelic therapy that is either entirely enthusiastic or entirely critical.
Neither feels true to me.
What I see instead is something more layered:
There is real potential for healing.
There is also real potential for harm.
There are thoughtful practitioners doing careful work.
There are also systems moving faster than they can fully hold.
There is hope here.
And there are ethical questions that are not optional.
Both belong in the conversation.
A Slower, More Human Approach to Psychedelic Integration
We are in a moment where access to psychedelic therapy will likely continue to expand.
Policies will change. Research will grow. More people will seek these experiences.
And alongside that, there is a quieter invitation:
To slow down.
To pay attention to what these experiences actually open.
To recognize that healing doesn’t happen in a single session, no matter how profound.
And to create space for integration—not as an afterthought, but as the heart of the work.
Because in the end, it’s not just about what happens in an altered state.
It’s about whether that experience can be held, understood, and woven into a life in a way that is truly supportive.
That kind of healing doesn’t move quickly.
And it can’t be fast-tracked.
About the Author
Sara Ouimette, LMFT is a depth psychotherapist in Oakland, California who specializes in working with highly sensitive people, healthcare professionals, and individuals seeking grief counseling or trauma therapy while navigating major life transitions. Her work is grounded in Jungian depth psychology and focuses on helping people develop deeper self-understanding and compassion for the unseen parts of their lives. Sara also offers psychedelic integration therapy, supporting individuals in making sense of meaningful psychedelic experiences and integrating those insights into everyday life.